Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Intro slide
- Models of AD
- I - key facets of AD pathogenesis
- Pathogenic pathways
- A-beta peptide
- Neurofibrillary tangles
- AD genes
- A-beta derived by APP endoproteolysis
- BACE 1 is beta-secretase
- Gamma-cleavage of APP
- Gamma-secretase has many substrates
- Two ways for APP processing
- Tauopathies
- Simple pathogenic pathway for AD
- II - animal models of AD
- Why transgenic and why mice?
- Technical aspects of transgenesis
- Creation of transgenic APP mice
- Amyloid peptide in aging mice
- Morris water maze test
- Learning acquisition
- Creation of NFT-depositing mice
- Tangles, frontal cortex
- Astrocytic pathologies
- Encoded protein effects neuroanatomical position
- From A-beta to tau pathology
- III - new insights into pathogenesis
- Testing effects on A-beta
- Copper and A-beta
- Mutant mice with elevated copper
- Effects of copper on CSF A-beta
- Elevated copper and reduced plaque
- Conclusions
- Relationship between copper and pathogenesis
- Presenilin-1 transgenics
- Presenilin-2 transgenics
- PS1/PS2 and APP fragments
- IV - A-beta directed therapies
- AD vaccination studies
- Immunization with A-beta 1-42
- A-beta immunization of TgCRND8 mice
- Immunization 2000-2002
- A-beta antibodies inhibit fibril formation
- Epitope mapping of A-beta
- Immunotherapy of "Alzheimer" mice
- Pathogenic pathways
- AD pathogenesis scheme
- Acknowledgements
- References
Topics Covered
- Animal models and AD research
- Role in identifying pathological pathways, biomarkers and candidate therapies
- Design of models and associated technical parameters
- Process of transgenesis
- Developing mouse models for beta-amyloid precursor protein mutations
- TgCRND8 mice
- Transgenic approaches for investigating Tau mutations
- Exploring environmental modifiers of beta-amyloid pathobiology
- Candidate chemical risk-factor for sporadic AD
- Potential of ''smart'' beta-amyloid-directed interventions
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Westaway, D. (2007, October 1). Experimental therapies in Alzheimer's disease: the development and use of mouse models [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/JLBH5133.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. David Westaway has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Experimental therapies in Alzheimer's disease: the development and use of mouse models
A selection of talks on Neurology
Hide